Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting - Day 2
Рет қаралды 14,713
Күн бұрынThe CTGTAC committee will meet in open session on both days to discuss the toxicity risks of adeno-associated virus (AAV) vector-based gene therapy products. The discussion topics include safety issues identified during preclinical and/or clinical evaluation, and oncogenicity risks due to vector genome integration.
Captioning:
www.captionedt...
U.S. Food and Drug Administration
Рет қаралды 32 М.
U.S. Food and Drug Administration
Рет қаралды 1,8 М.
U.S. Food and Drug Administration
Рет қаралды 1,4 М.
U.S. Food and Drug Administration
Рет қаралды 1 М.
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic aci...
U.S. Food and Drug Administration
Рет қаралды 503
U.S. Food and Drug Administration
Рет қаралды 1 М.
U.S. Food and Drug Administration
Рет қаралды 740
U.S. Food and Drug Administration
Рет қаралды 641
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...
U.S. Food and Drug Administration
Рет қаралды 671
U.S. Food and Drug Administration
Рет қаралды 736
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adul...
U.S. Food and Drug Administration
Рет қаралды 391